Last reviewed · How we verify
ESG206
ESG206 is a small molecule targeting the SGLT2 receptor.
ESG206 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | ESG206 |
|---|---|
| Also known as | ESG206-2 |
| Sponsor | Shanghai Escugen Biotechnology Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, ESG206 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly relevant for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome (PHASE2)
- A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (PHASE1)
- A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (PHASE1)
- A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESG206 CI brief — competitive landscape report
- ESG206 updates RSS · CI watch RSS
- Shanghai Escugen Biotechnology Co., Ltd portfolio CI